BioSyent (RX.V) Akcie Kurz
BioSyent Kurz
Tržby rostly o 19,3 % ročně za posledních 19 let na 43,05 Mil. CAD. Zisk na akcii rostl o 18,6 % ročně za posledních 19 let. čistá marže společnosti BioSyent je nyní 20,9 %, dolů z 21,9 % před několika lety. BioSyent aktuálně nabízí dividendový výnos kolem 1,17 %. Výplatní poměr je kolem 25 % zisku. Dividenda rostla o 71,0 % ročně za posledních 3 let. Medián cílové ceny analytiků je 16,83 CAD, tedy pod aktuální cenu o 1,5 %. Z 7 analytiků jich 6 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie BioSyent
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model BioSyent a analýza akcií
Nejčastější otázky týkající se akcie BioSyent
The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.
Biosyent Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biosyent Inc in the market include pharmaceutical companies like Apotex Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V.
Biosyent Inc is a pharmaceutical company based in Canada. It was founded in 2004 and has since become a leader in the specialty pharmaceutical industry. The company focuses on acquiring or in-licensing niche pharmaceutical products, with a goal to provide reliable and effective therapeutic options to patients and healthcare professionals. Biosyent Inc has a successful track record of commercializing pharmaceutical products and has established a strong presence in the Canadian market. With a commitment to high-quality medications, Biosyent Inc continuously strives to meet the evolving healthcare needs of the population.
Biosyent Inc has achieved significant milestones since its inception. The company has successfully launched and commercialized multiple pharmaceutical and healthcare products in Canada. This includes obtaining regulatory approvals for important drugs, expanding their product portfolio, and establishing strategic partnerships with global pharmaceutical companies. Biosyent Inc has also demonstrated consistent revenue growth and increased market share, highlighting its strong performance in the industry. With their commitment to innovation and delivering high-quality products, Biosyent Inc continues to contribute to the advancement of healthcare and pharmaceuticals.
Biosyent Inc is primarily present in Canada and the United States.
Biosyent Inc is a pharmaceutical company that values innovation, sustainability, and customer-centricity. Their corporate philosophy revolves around providing high-quality, niche pharmaceutical products to meet the evolving healthcare needs of patients. With a focus on sourcing and licensing unique product opportunities, Biosyent Inc has built a strong reputation as a reliable partner within the healthcare industry. By utilizing their expertise in regulatory affairs and product commercialization, Biosyent Inc strives to improve patient outcomes while delivering value to their shareholders.
Analytici aktuálně stanovují průměrnou cílovou cenu 16,83 CAD pro akcii BioSyent (medián: 16,83 CAD), tedy -1,5 % vůči poslední ceně. Konsensus vychází z 7 hodnocení analytiků.
7 analytiků aktuálně hodnotí akcii BioSyent: 6 doporučuje koupit, 1 držet a 0 prodat. Pro rok 2026 analytici očekávají u BioSyent tržby 73,20 Mil. CAD a zisk na akcii 1,05 CAD.
Při aktuálním kurzu se akcie BioSyent obchoduje za 10,97 EUR (17,09 CAD).
Akcie BioSyent (RX.V) je kótována na 2 burzách, mimo jiné: Toronto (RX.V).
Biosyent Inc is a pharmaceutical company headquartered in Canada that focuses on the development, marketing, and distribution of innovative products. The company specializes in medications in the areas of dermatology, gastroenterology, urology, and pain management. The business strategy of Biosyent Inc is to bring new products to the market that are needed by the growing number of patients and healthcare providers. In addition, the company also produces generics, which it offers at lower costs than the originals. Biosyent Inc aims to improve the lives of patients through better healthcare solutions. The company is active in various regions and works with partners in Canada, the US, and Europe. Through targeted investments and marketing initiatives, Biosyent Inc has managed to expand its reach and diversify its offerings. The company collaborates closely with physicians, pharmacies, and customers to tailor its offerings to their needs. In the field of dermatology, the company offers preparations for acne, eczema, psoriasis, and other skin problems. In gastroenterology, Biosyent Inc has developed medications that can be used to treat gastrointestinal diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. In urology, the company offers a solution for erectile dysfunction, and in pain management, it provides effective opioid antagonists in the form of nasal sprays and sublingual tablets. In addition to pharmaceutical products, Biosyent Inc also offers diagnostics and a solution for measuring urine flow. To further improve its products, the company also invests in researching new technologies and therapy forms. The company has a strong research and development department that works closely with the marketing and sales departments. Biosyent Inc strategically invests in the search for new active ingredients and solutions to continue offering its customers innovative products. Furthermore, the company works on optimizing its production processes and increasing its efficiency. The divisions of Biosyent Inc include: - Dermatology - Gastroenterology - Urology - Pain management Biosyent Inc. focuses on diversifying its offerings and producing innovative products that meet the needs of patients. Through the use of new technologies and procedures, the company aims to continue growing and strengthening its position in the market.
Tržby očekávané za BioSyent činí 73,20 Mil. CAD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za BioSyent činí 11,81 Mil. CAD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) BioSyent je aktuálně 16,30. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie BioSyent.
Poměr ceny k tržbám (P/S) BioSyent je aktuálně 2,63. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie BioSyent.
Score kvality pro BioSyent je 10/10.
ISIN BioSyent je CA0906901081. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN BioSyent je A1J6DY. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker BioSyent je RX.V. Symbol tickeru se používá k obchodování akcií BioSyent na burze.
BioSyent akcie
BioSyent Peer Group
BioSyent Ticker
BioSyent FIGI
Všechny fundamentální údaje o BioSyent v podrobné analýze
Naše analýzy akcií společnosti BioSyent zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti BioSyent. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: